Stockreport

Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating. The firm credited the anticipated 2026 [Read more]